SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-040100
Filing Date
2023-11-09
Accepted
2023-11-09 17:02:56
Documents
13
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 44991
2 ex99-1.htm EX-99.1 127872
  Complete submission text file 0001493152-23-040100.txt   361830

Data Files

Seq Description Document Type Size
3 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ensc-20231109.xsd EX-101.SCH 3012
4 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ensc-20231109_lab.xml EX-101.LAB 34240
5 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ensc-20231109_pre.xml EX-101.PRE 22357
7 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3431
Mailing Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037
Business Address 7946 IVANHOE AVENUE SUITE 201 LA JOLLA CA 92037 (858) 263-4196
Ensysce Biosciences, Inc. (Filer) CIK: 0001716947 (see all company filings)

IRS No.: 822755287 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38306 | Film No.: 231393596
SIC: 2834 Pharmaceutical Preparations